drugset / Trial / NCT00904085

Post-operative Efficacy and Safety Study

NCT00904085

Phase 3 Completed 122 enrolled Endo USA Inc., a Keenova Therapeutics Company
RandomizedSingle-groupDouble-blindTreatment

Summary

The purpose of this study was to compare the analgesic efficacy of 5 mg oxymorphone IR with placebo in patients with mild to moderate pain following outpatient knee arthroscopy.

Timeline

Start
2003-04
Primary completion
2003-06
Completion
2003-06

Drugs

EvaluationDrugModalityDoseRoute
Comparator Oxymorphone Small molecule 5 mg

Indications

No indication recorded.